Insmed INSM
NASDAQ INSM
$111.12 +2.53 (+2.33%)
At close: Oct 2, 2026 · 4:00 PM EDT

Insmed (INSM) Gains from Sales and Divestitures (2011 - 2013)

Updated

Insmed (INSM) posted Gains from Sales and Divestitures of -$9,000 for FY2014, compared with $2,000 in FY2013.

Analysis

Insmed (INSM) Gains from Sales and Divestitures (2011 - 2013) Analysis & Trends

Since FY2011, Insmed has reported Gains from Sales and Divestitures for 4 years.

  • Business Quant data shows INSM's Gains from Sales and Divestitures at $2,000 in FY2013 (-60.0%), $5,000 in FY2012 (+400.0%) and $1,000 in FY2011.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Insmed 24.26 Bn 18.76 Bn 358.27 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2013 2,000.00
Mar 31, 2012 5,000.00
Dec 31, 2011 1,000.00
API Access

Insmed Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=INSM&period=max&api_key=YOUR_API_KEY